EUVIMEDEUVIMED entdecken
Crossref

Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy

Zhixiong Gao, Hanwei Huang, Ying Zhi iD, Hu Wu, Yongcheng Guo, Yanhao Dong, Yuhang Du, Zao Ji, Shihua Yang, Yaohe Wang, Zhenguo Cheng, Huiling Gao iD und 4 weitere

ACS Nano · 18.08.2026 · 20 (32) · 22391-22412

DOI: 10.1021/acsnano.5c21715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 06.08.2026. Verfasst von Zhixiong Gao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Sheny…. Hauptthemen laut MEDLINE: Immunotherapy, Oncolytic Viruses, Neoplasms, Transcription Factors. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Department of Science and Technology of Liaoning Province, National Basic Research Program of China (973 Program), National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of proteolysis-targeting chimeras (PROTACs) represents a promising strategy for targeted protein degradation in cancer therapy. However, the limited tumor-specific targeting and the inherent unfavorable physicochemical properties of PROTACs lead to insufficient cellular uptake and suboptimal antitumor immune responses. Herein, as a proof of concept, we developed an oncolytic virus-PROTAC conjugate (BPAD) by efficiently coupling bromodomain-containing protein 4 (BRD4)-targeting PROTACs with oncolytic viruses (OVs). In BPAD, the potent and highly selective infection of OVs to tumor cells enhances both cellular uptake and tumor-selective delivery of PROTACs, resulting in a 640-fold increase in the protein degradation efficiency. Moreover, prior to OV-induced tumor lysis, the preferential replication of OVs within tumor cells, combined with BRD4 degradation, promotes the secretion of type I interferons and facilitates dendritic cell maturation. Overall, the BPAD strategy enables the development of biologically derived macromolecular PROTAC conjugates, thereby enhancing the clinical translation potential of diverse PROTACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyOncolytic VirusesNeoplasmsTranscription FactorsAntineoplastic AgentsOncolytic VirotherapyHumansProteolysis Targeting ChimeraAnimalsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorProteolysis

Stichwörter der Autor:innen

antitumor efficacyimmunotherapyoncolytic virusproteolysis-targeting chimerassmall molecular drugs

Substanzen

Proteolysis Targeting ChimeraBromodomain Containing ProteinsCell Cycle ProteinsBRD4 protein, humanTranscription FactorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang110001, China.
  • Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, 155 North Nanjing Street, Heping District, Shenyang110001, China.
  • Phase I Clinical Trials Center, The First Hospital, China Medical University, 518 North Chuangxin Road, Baita Street, Hunnan District, Shenyang, Liaoning110102, China.
  • Chemical Biology Center, School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan250117, China.
  • Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu221002, China.
  • Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, LondonEC1M 6BQ, U.K.

ORCID-Profile: Ying Zhi, Huiling Gao, Funan Liu

Förderung

  • Department of Science and Technology of Liaoning Province
  • National Basic Research Program of China (973 Program)
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Gao, Z., Huang, H., Zhi, Y., Wu, H., Guo, Y., Dong, Y., Du, Y., Ji, Z., Yang, S., Wang, Y., Cheng, Z., Gao, H., Jiang, X., Jiang, M., Zhao, K., & Liu, F. (2026). Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy. ACS Nano, 20(32), 22391-22412. https://doi.org/10.1021/acsnano.5c21715

Vancouver

Gao Z, Huang H, Zhi Y, Wu H, Guo Y, Dong Y, et al. Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy. ACS Nano. 2026;20(32):22391-22412. doi:10.1021/acsnano.5c21715

BibTeX
@article{Gao2026,
  author = {Gao, Zhixiong and Huang, Hanwei and Zhi, Ying and Wu, Hu and Guo, Yongcheng and Dong, Yanhao and Du, Yuhang and Ji, Zao and Yang, Shihua and Wang, Yaohe and Cheng, Zhenguo and Gao, Huiling and Jiang, Xinyi and Jiang, Min and Zhao, Kun and Liu, Funan},
  title = {Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy},
  journal = {ACS Nano},
  year = {2026},
  volume = {20},
  number = {32},
  pages = {22391--22412},
  doi = {10.1021/acsnano.5c21715}
}
Kostenlos starten →